[1]白嘉琪?张闯 陈海威 徐红波 汪奇.鱼精蛋白在心脏外科和介入手术中的应用进展[J].心血管病学进展,2026,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.003]
　BAI Jiaqi,ZHANG Chuang,CHEN Haiwei,et al.Progress in the Application of Protamine in Cardiac Surgery and Interventional Procedures[J].Advances in Cardiovascular Diseases,2026,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2026.01.003]
点击复制

鱼精蛋白在心脏外科和介入手术中的应用进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2026年1期
页码:
11
栏目:
综述
出版日期:
2026-01-25

文章信息/Info

Title:
Progress in the Application of Protamine in Cardiac Surgery and Interventional Procedures
作者:
白嘉琪1?张闯 1 陈海威 1 徐红波 2 汪奇 1
(1.中国人民解放军总医院第六医学中心心内科,北京,100048;2.66028部队勤务保障营卫生连,河北 承德,067000)
Author(s):
BAI Jiaqi1; ZHANG Chuang1; CHEN Haiwei1; XU Hongbo2; WANG Qi1
(1Department of Cardiology,The Sixth Medical Center of Chinese PLA General Hospital,Beijing 100048,China;2. Sanitary Company,Logistics Support Battalion,Troop 66028Chengde 067000,Hebei,China)
关键词:
肝素; 鱼精蛋白; 心脏外科; 心脏介入
Keywords:
Heparin;  Protamine;  Cardiac Surgery;  Cardiac Intervention
DOI:
10.16806/j.cnki.issn.1004-3934.2026.01.003
摘要:
心脏手术围术期抗凝管理的优化是保障手术安全的关键。肝素是经典的抗凝剂，它通过抑制凝血级联反应在术中应用广泛。鱼精蛋白作为其特异性拮抗剂，能通过电荷中和机制快速逆转抗凝效应，恢复凝血功能。当前面临的问题主要包括鱼精蛋白应用剂量的个体化不足、缺乏统一标准以及在不同介入手术中的应用难题。现深入探讨鱼精蛋白在心外科手术和心脏介入手术中的差异化应用，提出未来研究方向的建议，为优化心脏围术期抗凝管理提供理论依据和实践指导，以期提高手术安全性，改善患者预后。
Abstract:
Optimizing anticoagulation management during the perioperative period of cardiac surgery is crucial for ensuring surgical safety. Heparin,a classic anticoagulant,is widely used in surgery due to its ability to inhibit the coagulation cascade. Protamine,as its specific antagonist,can rapidly reverse the anticoagulant effect and restore coagulation function through a charge neutralization mechanism. Current challenges mainly include insufficient individualization of protamine dosage,lack of unified standards,and difficulties in its application across different interventional procedures. This paper explores the differential use of protamine in cardiac surgery and cardiac intervention and proposes suggestions for future research directions,providing theoretical basis and practical guidance to optimize anticoagulation management in the perioperative period of cardiac surgery,with the aim of enhancing surgical safety and improving patient outcomes

参考文献/References:

[1] Sultana R,Kamihira M. Multifaceted heparin:diverse applications beyond anticoagulant therapy[J]. Pharmaceuticals (Basel),2024,17(10):1362.

[2]Chabata CV,Yu H,Ke L,et al. Andexanet alfa-associated heparin resistance in cardiac surgery:mechanism and in vitro perspectives[J]. Arterioscler Thromb Vasc Biol,2025,45(1):144-156.

[3]Cartwright B,Mundell N. Anticoagulation for cardiopulmonary bypass:part one[J]. BJA Educ,2023,23(3):110-116.

[4] Heestermans M ,Poenou G,Hamzeh-Cognasse H,et al. Anticoagulants:a short history,their mechanism of action,pharmacology,and indications[J]. Cells,2022,11(20):3214.

[5]Chen Y,Phoon PHY,Hwang NC. Heparin resistance during cardiopulmonary bypass in adult cardiac surgery[J]. J Cardiothorac Vasc Anesth,2022,36(11):4150-4160.

[6]Shadman H,Gallops CE,Ziebarth JD,et al. Exploring structures and dynamics of protamine molecules through molecular dynamics simulations[J]. ACS Omega,2022,7(46):42083-42095.

[7]Levy JH,Ghadimi K,Kizhakkedathu JN,et al. What’s fishy about protamine? Clinical use,adverse reactions,and potential alternatives[J]. J Thromb Haemost,2023,21(7):1714-1723.

[8]Crivellari M,Landoni G,D’Andria Ursoleo J,et al. Protamine and heparin interactions:a narrative review[J]. Ann Card Anaesth,2024,27(3):202-212.

[9]Bekka E,Liakoni E. Anticoagulation reversal (vitamin K,prothrombin complex concentrates,idarucizumab,andexanet-α,protamine) [J]. Br J Clin Pharmacol,2025,91(3):604-614.

[10]Giustino G,Sabik JF 3rd,Serruys PW,et al. Major bleeding and mortality after revascularization of left main disease[J]. J Am Coll Cardiol,2024,84(24):2335-2346.

[11]Heidary Moghadam R,Mohammadi A,Salari N,et al. The prevalence of bleeding after percutaneous coronary interventions:A systematic review and meta-analysis[J]. Indian Heart J,2024,76(1):16-21.

[12]Thanh NVT,Hong MK,Ko YG. Optimal antithrombotic therapy after transcatheter aortic valve replacement:a comprehensive review[J]. Front Cardiovasc Med,2025,12:1528071.

[13]Wahba A,Kunst G,De Somer F,et al. 2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery[J].Interdiscip Cardiovasc Thorac Surg,2025,40(2):ivaf002.

[14]Arachchillage DJ,Kitchen S. Pleiotropic effects of heparin and its monitoring in the clinical practice[J]. Semin Thromb Hemost,2024,50(8):1153-1162.

[15]Lee MH,Beck M,Shann K. Protamine dose to neutralize heparin at the completion of cardiopulmonary bypass can be reduced significantly without affecting post-operative bleeding[J]. J Extra Corpor Technol,2023,55(3):105-111.

[16]Kjellberg G,Holm M,Fux T,et al. Calculation algorithm reduces protamine doses without increasing blood loss or the transfusion rate in cardiac surgery:results of a randomized controlled trial[J]. J Cardiothorac Vasc Anesth,2019,33(4):985-992.

[17]Hartmann J,Curzen N. Modified thromboelastography for peri-interventional assessment of platelet function in cardiology patients:a narrative review[J]. Semin Thromb Hemost,2023,49(2):192-200.

[18]Ramanujam V,DiMaria S,Varma V. Thromboelastography in the perioperative period:a literature review[J]. Cureus,2023,15(5):e39407.

[19]De Simone F,Nardelli P,Licheri M,et al. Less is more:we are administering too much protamine in cardiac surgery[J]. Ann Card Anaesth,2021,24(2):178-182.

[20]Boer C,Meesters MI,Veerhoek D,et al. Anticoagulant and side-effects of protamine in cardiac surgery:a narrative review[J]. Br J Anaesth,2018,120(5):914-927.

[21]Vespe MW,Stone ME,Lin HM,et al. Accurate protamine:heparin matching (not just smaller protamine doses) decreases postoperative bleeding in cardiac surgery; results from a high-volume academic medical center[J]. Perfusion,2024,39(7):1335-1347.

[22]Dasgupta S,Samad A,Howlader SS,et al. Complete heparin reversal by protamine during Off-Pump Coronary Artery Bypass surgery (OPCAB):a necessity or myth?[J]. Mymensingh Med J,2023,32(2):421-429.

[23]Mondal S,Abuelkasem E,Vesselinov R,et al. Protamine dosing and its impact in cardiac surgery transfusion practice—A retrospective bi-institutional analysis[J]. Transfusion,2024,64(3):467-474.

[24]Miles LF,Burt C,Arrowsmith J,et al. Optimal protamine dosing after cardiopulmonary bypass:the PRODOSE adaptive randomised controlled trial[J].?PLoS Med,2021,18(6):e1003658.

[25]Jain P,Silva-De Las Salas A,Bedi K,et al. Protamine dosing for heparin reversal after cardiopulmonary bypass:a double-blinded prospective randomized control trial comparing two strategies[J].?Anesthesiology,2025,142(1):98-106.

[26]陈小莉,陈东,郭仲辉,等. 鱼精蛋白半量负荷剂量加半量微泵输注法中和肝素的效果[J]. 安徽医学,2020,41(1):46-49.

[27]郭大雷,刘岩,苏丕雄,等.肝素残留在非体外循环冠状动脉旁路移植术围手术期的利弊分析[J]. 中华胸心血管外科杂志,2020,36(3):180-184.

[28]Jiang Y,Lu Y,Jia X,et al. The emerging role of adopting protamine for reducing the risk of bleeding complications during the percutaneous coronary intervention:a meta-analysis[J]. J Card Surg,2022,37(12):5341-5350.

[29]Choi JH,Chun KJ,Jung SM,et al. Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention[J]. BMC Cardiovasc Disord,2022,22(1):207.

[30]Lee PY,Bello J,Ye C,et al. Safety of routine protamine in the reversal of heparin in percutaneous coronary intervention:a systematic review and meta-analysis[J]. Int J Cardiol,2023,388:131168.

[31]Wang H,Cui C,Lu D,et al. Safety analysis of brachial artery sheath removal after heparin reversal with a half dose of protamine after percutaneous coronary intervention:a single-center experience[J]. Front Cardiovasc Med,2025,11:1479506.

[32]Liu M,Wang H,Gao L,et al. Intravenous protamine sulfate shortens compression time after coronary angiography via distal transradial access[J]. CVIA,2025,10(1):996.

[33]Lemmert ME,van Bommel RJ,Diletti R,et al. Clinical characteristics and management of coronary artery perforations:a single-center 11-year experience and practical overview[J]. J Am Heart Assoc,2017,6(9):e007049.

[34]Itoh T,Kanaya Y,Komuro K,et al. Kounis syndrome caused by protamine shock after coronary intervention:a case report[J]. J Cardiol Cases,2021,25(1):23-25.

[35]中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 经皮冠状动脉介入治疗指南（2025）[J]. 中华心血管病杂志,2025,53(7):717-745.

[36]Al-Kassou B,Veulemans V,Shamekhi J,et al. Optimal protamine-to-heparin dosing ratio for the prevention of bleeding complications in patients undergoing TAVR—A multicenter experience[J]. Clin Cardiol,2023,46(1):67-75.

[37]Kneizeh K ,Milzi A,Vogt F,et al. Efficacy and safety of low-dose protamine in reducing bleeding complications during TAVI:a propensity-matched comparison[J]. J Clin Med,2023,12(13):4243.

[38]Vriesendorp PA,Nanayakkara S,Heuts S,et al. Routine protamine administration for bleeding in transcatheter aortic valve implantation:the ACE-PROTAVI randomized clinical trial[J]. JAMA Cardiol,2024,9(10):901-908.

[39]Chauhan S,Bhatnagar M,Jilani TN,et al. Annular rupture due to calcified nodule located in left ventricular outflow tract (LVOT) during transcatheter aortic valve replacement (TAVR) managed by protamine sulfate[J]. Cureus,2023,15(1):e33417.

[40]Yoshida T,Matsuura K,Mandour AS,et al. Hemodynamic effects of protamine infusion in dogs with myxomatous mitral valve disease undergoing mitral valvuloplasty[J]. Vet Sci,2022,9(4):178.

[41]Kallur AS,Bhogal S,Waksman R,et al. Protamine-induced acute thrombosis in a post-TAVR patient:a word of caution[J]. Cardiovasc Revasc Med,2023,53S:S171-S173.

[42]Yamada Y,Iemura J,Kambara A,et al. Association of postoperative atrial fibrillation with higher dosing ratios of protamine-to-heparin[J]. J Extra Corpor Technol,2023,55(1):23-29.

[43]Kermanshah A,Rubini Silva Ceschim M,Montes de Oca D,et al. Anaphylaxis to protamine during a carotid endarterectomy[J]. Cureus,2024,16(8):e68289.

[44]Erdem S,An SY,McAlister CA,et al. Suicide left ventricle following protamine:a case report[J]. Catheter Cardiovasc Interv,2023,101(3):592-595.

相似文献/References:

[1]段安琪 罗勤 赵智慧 赵青 柳志红.体外膜肺氧合支持下肝素诱导的血小板减少症研究进展[J].心血管病学进展,2021,(12):1157.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.001]
　DUAN Anqi,LUO Qin,ZHAO Zhihui,et al.Heparin-Induced Thrombocytopenia in Patients Receiving Extracorporeal Membrane Oxygenation[J].Advances in Cardiovascular Diseases,2021,(1):1157.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.001]
[2]程若熙 龚俊荣 陈桂花 张俐.心房颤动导管消融术中ACT指导阶梯性抗凝方案与经验性抗凝方案的比较：一项倾向性评分匹配的观察性研究[J].心血管病学进展,2025,(11):1037.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.016]
　CHENG Ruoxi,GONG Junrong,CHEN Guihua,et al.Comparison of ACT-Guided Stepwise Anticoagulation Regimen and Empirical Anticoagulation Regimen During Catheter Ablation for Atrial Fibrillation: A Propensity Score Matching Observational Study[J].Advances in Cardiovascular Diseases,2025,(1):1037.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.016]

更新日期/Last Update: 2026-05-14